Back to top
more

Allogene Therapeutics (ALLO)

(Real Time Quote from BATS)

$3.04 USD

3.04
1,299,471

-0.33 (-9.79%)

Updated Apr 24, 2024 03:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Allogene Therapeutics (ALLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

How Allogene (ALLO) Stock Stands Out in a Strong Industry

by Zacks Equity Research

Allogene (ALLO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss

by Zacks Equity Research

Allogene's (ALLO) fourth-quarter earnings beat estimates, but sales miss the mark. Management expects operating expenses for 2024 to be around $280 million.

Allogene Therapeutics (ALLO) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 8.51% and 54.35%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology

by Zacks Equity Research

Allogene (ALLO) intends to combine its next generation AlloCAR T platform with Arbor Biotechnologies' proprietary CRISPR gene therapy technology to develop therapies for autoimmune diseases.

Clene Inc. (CLNN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Clene Inc. (CLNN) delivered earnings and revenue surprises of 14.29% and 21.43%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Allogene Therapeutics (ALLO)'s Technical Outlook is Bright After Key Golden Cross

by Zacks Equity Research

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

How Allogene (ALLO) Stock Stands Out in a Strong Industry

by Zacks Equity Research

Allogene (ALLO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Allogene (ALLO) Down 20% on Strategic Changes in Pipeline

by Zacks Equity Research

Allogene (ALLO) decides to deprioritize two pivotal studies for the third-line treatment of certain lymphoma patients and start a new study to focus on the first-line treatment of the indication.

Is Aligos Therapeutics (ALGS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Aligos Therapeutics, Inc. (ALGS) and Allogene Therapeutics (ALLO) have performed compared to their sector so far this year.

The Zacks Analyst Blog Highlights Allogene Therapeutics, Arcutis Biotherapeutics and C4 Therapeutics

by Zacks Equity Research

Allogene Therapeutics, Arcutis Biotherapeutics and C4 Therapeutics are part of the Zacks top Analyst Blog.

Sundeep Ganoria headshot

3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying

by Sundeep Ganoria

We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024 following signals of a stabilizing market.

Ekta Bagri headshot

3 Cancer-Focused Biotechs That Appear Promising Bets for 2024

by Ekta Bagri

With the spotlight on oncology-focused companies in the biotech sector in 2023, we discuss three stocks that have a promising oncology portfolio/pipeline for 2024.

Atara Biotherapeutics (ATRA) Slumps 57% in a Month: Here's Why

by Zacks Equity Research

Atara's (ATRA) shares fell after a phase II study evaluating its multiple sclerosis therapy did not meet its primary endpoint.

Gain Therapeutics (GANX) Down 25% on Issue of New Common Stock

by Zacks Equity Research

Gain Therapeutics (GANX) to issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $9.4 million in gross proceeds from this issue.

Karuna (KRTX) Posts Upbeat Safety Data on Schizophrenia Drug

by Zacks Equity Research

Data from an early-stage study shows that treatment with Karuna's (KRTX) KarXT was not associated with clinically meaningful increases in blood pressure in schizophrenia patients.

Merck (MRK) Gets FDA Nod for Keytruda Expansion in Gastric Cancer

by Zacks Equity Research

Following this approval, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers. Overall, the drug is approved for 38 indications in the country.

Allogene Therapeutics (ALLO) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

Allogene Therapeutics (ALLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Esperion (ESPR) Q3 Earnings Beat, Stock Up on Strong Revenues

by Zacks Equity Research

Esperion's (ESPR) third-quarter earnings and revenues beat estimates on the back of better-than-expected collaboration revenues. The company reiterates its financial guidance for 2023.

Iovance's (IOVA) Meets Q3 Earnings, Lags Sales Estimates

by Zacks Equity Research

Iovance's (IOVA) third-quarter earnings meet estimates, but sales miss the same.

Allogene's (ALLO) Q3 Loss Narrower Than Expected, Sales Miss

by Zacks Equity Research

Allogene's (ALLO) third-quarter earnings beat estimates, but sales miss the same. Management reiterated its previously issued financial guidance for 2023.

Evelo (EVLO) Drops 59% on Flunking Psoriasis Drug Study

by Zacks Equity Research

Evelo's (EVLO) EDP2939 fails to achieve the primary endpoint in a mid-stage for treating moderate psoriasis. The company decides to cease clinical development on the candidate.

Merck's (MRK) Keytruda Gets FDA Nod in Sixth NSCLC Indication

by Zacks Equity Research

FDA has approved the expanded use of Merck's (MRK) Keytruda in certain patients with early-stage non-small cell lung cancer who can get their tumors removed surgically.

CHMP Endorses Merck's (MRK) Keytruda Expansion in Gastric Cancer

by Zacks Equity Research

If approved, Merck's (MRK) Keytruda will be approved for a second indication in advanced gastric or GEJ cancer.

The Zacks Analyst Blog Highlights Pfizer, Allogene Therapeutics and Corcept Therapeutics

by Zacks Equity Research

Pfizer, Allogene Therapeutics and Corcept Therapeutics are included in this Analyst Blog.